42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE
Idiopathic Pulmonary Fibrosis
Lakefront Biotherapeutics NVSmall moleculePhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
111 Active assets in the Idiopathic Pulmonary Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pirfenidone Endeavor Biomedicines, Inc. | Phase 4 | A |
N-Acetyl-L-Cysteine Endeavor Biomedicines, Inc. | Phase 4 | BBB |
Nintedanib Mannkind Corporation | Phase 4 | BBB |
Nerandomilast Boehringer Ingelheim | Phase 3 | BB |
hsk44459 Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
42-ETHYL-14-FLUORO-83-HYDROXY-3,48-DIMETHYL-7-OXO-3-AZA-4(3,6)-IMIDAZO(1,2-A)PYRIDINA-5(1,4)-PIPERAZINA-2(4,2)-(1,3)THIAZOLA-8(1)-AZETIDINA-1(1)-BENZENAOCTAPHANE-25-CARBONITRILE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →